knowledge -WSS

knowledge

author：comprehensive 2025-10-02 22:40:36 - browse：1

Bristol Myers Squibb sign — Courtesy Bristol Myers Squibb

Bristol Myers Squibb said that it would purchase Mirati Therapeutics, maker of the cancer drug Krazati, for $4.8 billion in cash in a deal that shows the continued interest of large pharmaceutical firms in relatively small “bolt-on” acquisitions.

Bristol said that it would pay $58.00 per share for Mirati, and would hold another $12.00 per share, or a total of $1 billion, to be paid if one of two different applications for an additional use for Krazati is approved within seven years after the merger closes.

Chris Boerner, Bristol’s chief operating officer and CEO-elect, said in a statement that Mirati had several cancer drugs in development that could deliver sales in the latter half of the decade and beyond, when investors worry that Bristol will need new products to sustain its growth.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Reframing the conversation around gain

WSS

Key lawmaker blasts Congress’ efforts on addiction: ‘Shame on us’

Prosecutors say FTX founder Sam Bankman

Divers poised to search for children washed away in Pennsylvania flash flood

What is the Turing Test that determines if computers can think?

How Brent Saunders' Allergan experiment failed

Dispute over threat of extinction posed by artificial intelligence looms over surging industry

focus

knowledge

focus

Tori Bowie and the unacceptable rates of Black maternal death

Why Marc Tessier

Jerome Adams on the need for new antivirals for Covid

Grand jury probing Trump's efforts to overturn 2020 election did not meet Friday: Sources

In age of alternative facts, a scholarly course on calling out crap

Prosecutors say FTX founder Sam Bankman

Psychedelics group wrestles with new pharma identity

Study identifies new proteins linked to dementia risk 25 years later

Psychedelics group wrestles with new pharma identity

Biden White House, tech companies launch new safeguards around emerging AI technology

focus

Prosecutors say FTX founder Sam Bankman

A new deal aims to ramp up use of AI in rehab care decisions

New chief aims to remake Sanofi Genzyme

Why the advice to take all your antibiotics may be wrong

Reframing the conversation around gain

Florida babysitter arrested over hot car death, authorities say

knowledge

explore

hotspot

entertainment